Disease relevance of Fibrocystic Breast Disease

• The association was specific to fibrocystic breast disease in that there was no association of caffeine consumption with fibroadenoma or other forms of benign breast disease [1].
• For investigation of the bioactivity of circulating prolactin and growth hormone (lactogenic hormones) in symptomatic benign breast disease, serum was assayed by the Nb2 lymphoma cell method in premenopausal patients with cystic breast disease and cyclic mastalgia and in normal premenopausal women [2].
• These results suggest that GCDFP-15 and EMA could be the biochemical expression of apocrine metaplasia and epithelial hyperplasia, respectively, two histopathological features which characterize breast cystic disease [3].
• RT-PCR amplicons of MMP-2 and TIMP-2 mRNA from tissue biopsies of 13 breast carcinomas and one fibrocystic mastopathy were quantitated [4].
• To determine the potential role of 34BE12 in the breast, we studied by immunohistochemistry 19 tubular carcinomas, 14 radial scars, two microglandular adenoses, and 9 sclerosing adenoses, using monoclonal antibodies to high molecular weight keratin, smooth muscle actin, type IV collagen, and antiserum to S100 protein [5].

High impact information on Fibrocystic Breast Disease

• Vitamin E relieves most cystic breast disease; may alter lipids, hormones [6].
• For examination of the effect of a low-fat diet on serum estrogen, progesterone, and gonadotropin levels, 16 patients with cystic breast disease and cyclic mastalgia were studied before dietary intervention and at 2 and 3 months thereafter [7].
• Effect of a low-fat diet on hormone levels in women with cystic breast disease. II. Serum radioimmunoassayable prolactin and growth hormone and bioactive lactogenic hormones [2].
• Endocrine parameters and alpha-tocopherol therapy of patients with mammary dysplasia [8].
• Fibrocystic breast disease following treatment with selective serotonin reuptake inhibitors [9].

Chemical compound and disease context of Fibrocystic Breast Disease

• Effects of exposure of neonatal mice to 17beta-estradiol on subsequent age-incidence and morphology of carcinogen-induced mammary dysplasia [10].
• Theophylline and fibrocystic breast disease [11].
• The biological significance of a major protein component in the fluid of gross cystic breast disease and a recognized marker of apocrine metaplasia, i.e. the 15-kDa glycoprotein (GCDFP-15), is presently unknown [12].
• Conjugated estrogens and fibrocystic breast disease [13].
• Sixty-three patients with severe breast dysplasia were treated with tamoxifen, 10 mg/day from day 5 to day 25 of the menstrual cycle for 4 months [14].

Biological context of Fibrocystic Breast Disease

• Increased frequencies were found for the B7 gene in the following prognostic groups: (a) lack of ER (0.08); (b) lack of PgR (0.09); (c) absence of mammary dysplasia (0.075); (d) histologic grade 3 (0.10); and (e) premenopause (0.12), the last two showing significant divergence from normal [15].
• In a hospital-based case-control study conducted in New Haven, Connecticut, women experiencing estrogen replacement therapy were found to be at twice the risk of nonusers for histologically confirmed fibrocystic breast disease (odds ratio = 2; 95 percent confidence limits = 1-3.9) if their menopause was natural [16].
• Human prolactin had no effect on the proliferation of one mastopathy but stimulates the cell growth of another fibrocystic mastopathy [17].
• Furthermore, invasive ductal carcinoma showed a markedly high number of tumor cells in the S-phase of the cell cycle, as compared to mammary dysplasia and fibroadenoma [18].

Anatomical context of Fibrocystic Breast Disease

• Effect of natural "micronized" progesterone on the chorionic gonadotropin concentrations in cyst fluids of women with gross cystic breast disease [19].
• In all TP rats, corpora lutea were absent in the ovaries. the incidence of mammary dysplasia in TP rats was 89.7% [20].
• Expression of connexin 43 in breast cancer in comparison with mammary dysplasia and the normal mammary gland [21].

Gene context of Fibrocystic Breast Disease

• The increased mammary tumor development is correlated with a 3-fold increase in the development of mammary dysplasia in Atm+/- compared with wild-type mice (P<0.05) [22].
• Twelve examples of microglandular adenosis (MA) were evaluated immunohistochemically using a panel of antibodies directed against actin, S-100 protein, collagen type IV, the c-erb-B2 gene product, and the progesterone receptor, as well as antibodies BER-EP4 and B72 [23].
• These results indicate that a high proportion of patients with fibrocystic breast disease exhibit increased daily prolactin secretion [24].
• The response to TRH in seven healthy female volunteers and in one patient with fibrocystic breast disease, was correlated with the mean serum prolactin levels over 24 hours [24].
• Two examples of mammary dysplasia (7%) showed foci of CEA positive acini [25].

Analytical, diagnostic and therapeutic context of Fibrocystic Breast Disease

• In a hospital-based case-control study that included 634 women with fibrocystic breast disease and 1,066 comparison women in Connecticut, the occurrence of fibrocystic breast disease was positively associated with average daily consumption of caffeine [1].
• For a chronic condition with so much variety of subjective sensitivity and great variability of objective clinical palpation, it is difficult to relate the amount of methyl xanthine consumption to "fibrocystic breast disease."[26]
• Ovariectomy (OVEX) of TP rats induced a significant and marked decrease in the incidence of mammary dysplasia (3.7%) [20].

References